A clinical trial update dated August 19, 2026 lists vasopressin in connection with the study titled "Impella Reverse Remodeling in End-Stage Heart Failure," registered as NCT06800716. The trial's current status is recruiting. No phase was specified in the available record.
According to the listing, the study is actively enrolling participants as of this update. No outcome data, efficacy findings, or safety results have been reported for this trial at this stage. The recruiting status indicates the study is ongoing and has not yet reached a stage where results would be posted.
Vasopressin is an approved compound, and its inclusion in this trial record reflects its role within the study's design or protocol as registered. This brief reports only the status and title as listed in the trial registry entry; it does not characterize any outcomes, benefits, or risks associated with the intervention. Readers seeking further detail on the trial's design, eligibility criteria, or objectives should consult the official registry listing directly.
For general background on this compound, see the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT06800716"]